Fuzeon+OB therapy was associated with a higher proportion of patients reaching < 400 copies/ ml (or < 50 copies/ ml) across all subgroups based on baseline CD4, baseline HIV-1 RNA, number of prior antiretrovirals (ARVs) or number of active ARVs in the OB regimen.